Rehmann Capital Advisory Group Acquires 709 Shares of Sanofi (NASDAQ:SNY)

Rehmann Capital Advisory Group boosted its holdings in Sanofi (NASDAQ:SNY) by 5.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,400 shares of the company’s stock after purchasing an additional 709 shares during the period. Rehmann Capital Advisory Group’s holdings in Sanofi were worth $799,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in the business. Cardinal Capital Management grew its position in Sanofi by 0.3% in the first quarter. Cardinal Capital Management now owns 69,004 shares of the company’s stock valued at $3,827,000 after purchasing an additional 199 shares in the last quarter. Gradient Investments LLC grew its position in Sanofi by 2.1% in the first quarter. Gradient Investments LLC now owns 9,764 shares of the company’s stock valued at $542,000 after purchasing an additional 200 shares in the last quarter. Providence Capital Advisors LLC grew its position in shares of Sanofi by 0.4% in the 4th quarter. Providence Capital Advisors LLC now owns 55,001 shares of the company’s stock valued at $2,653,000 after acquiring an additional 201 shares during the period. Perigon Wealth Management LLC grew its position in shares of Sanofi by 3.1% in the 1st quarter. Perigon Wealth Management LLC now owns 6,618 shares of the company’s stock valued at $367,000 after acquiring an additional 201 shares during the period. Finally, Beacon Financial Group grew its position in shares of Sanofi by 1.6% in the 1st quarter. Beacon Financial Group now owns 14,398 shares of the company’s stock valued at $799,000 after acquiring an additional 222 shares during the period. Institutional investors own 14.04% of the company’s stock.

Sanofi Trading Up 1.3%

SNY opened at $48.83 on Thursday. Sanofi has a fifty-two week low of $45.80 and a fifty-two week high of $60.12. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.37 and a quick ratio of 0.69. The firm has a market capitalization of $119.75 billion, a price-to-earnings ratio of 17.44, a PEG ratio of 1.10 and a beta of 0.48. The company’s 50 day moving average price is $50.28 and its two-hundred day moving average price is $52.07.

Sanofi (NASDAQ:SNY) last issued its earnings results on Thursday, April 24th. The company reported $0.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.90 by $0.04. The business had revenue of $10.41 billion for the quarter, compared to analyst estimates of $9.79 billion. Sanofi had a net margin of 14.56% and a return on equity of 17.15%. Sanofi’s revenue was down 11.0% on a year-over-year basis. During the same period in the prior year, the firm earned $1.78 earnings per share. As a group, research analysts predict that Sanofi will post 4.36 earnings per share for the current year.

Sanofi Increases Dividend

The firm also recently disclosed an annual dividend, which was paid on Thursday, June 12th. Shareholders of record on Friday, May 9th were issued a dividend of $2.0369 per share. This is an increase from Sanofi’s previous annual dividend of $1.48. The ex-dividend date was Friday, May 9th. This represents a yield of 3.1%. Sanofi’s dividend payout ratio is presently 57.14%.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. Guggenheim reissued a “buy” rating on shares of Sanofi in a research report on Tuesday, June 3rd. Hsbc Global Res raised shares of Sanofi to a “strong-buy” rating in a research report on Monday, April 28th. BNP Paribas began coverage on shares of Sanofi in a research report on Tuesday, April 15th. They issued an “outperform” rating and a $65.00 price objective for the company. The Goldman Sachs Group began coverage on shares of Sanofi in a report on Friday, March 21st. They set a “neutral” rating and a $65.00 target price for the company. Finally, Morgan Stanley set a $56.00 target price on shares of Sanofi in a report on Monday, June 2nd. Three research analysts have rated the stock with a hold rating, four have given a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $61.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.